Introduction
Glioma represent the most common and heterogeneous group of brain tumors emerging in adult human central nervous system. These tumors are traditionally classified according to their histopathology and the cell-type markers they express and lead to a complex classification theme. Nevertheless, glioma can roughly be subdivided into three major subgroups of different grades: (1) astrocytomas: pilocytic (grade I), diffuse (grade II), anaplastic (grade III) and glioblastoma multiform (GBM) (grade IV), (2) oligodendrogliomas (grade II and grade III), and (3) mixed oligoastrocytomas. This diversity of glioma correlates with a wide spectrum of mutated or affected cell signaling pathways observed in these neoplasms and also likely due to their different 'cell of origin' [1] . Moreover, in many cases, tumors which share a similar morphology and phenotype may have very different prognoses and responses to therapies. This underlines the need to redefine the criterions of the tumor classification which now will have to deal not only with a molecular and cellular analysis of the tumor bulk, but also on a better understanding of how tumors emerge, evolve over time and what cell types they arise from. Several recent studies have identified a tumorigenic CD133+ subpopulation of cancer cells regarded as tumor stem cells within GBM responsible for the initiation and development of those heterogeneous aggressive brain tumors [2] [3] [4] [5] . The presence of cancer stem cells in GBM may also explain the resistance of these tumors to radiotherapy and chemotherapy [6] . In contrast to glioblastomas, oligodendrogliomas are more sensitive to radiotherapy and alkylating agent chemotherapy [7, 8] . This variable therapeutic responsiveness has raised the hypothesis that oligodendroglioma and glioblastoma may have distinct origins.
Transgenic mouse and rat models using controlled ectopic expression of oncogenes in either precursor or maturing astrocytes have been used to model human glioblastoma, astrocytomas, oligodendrogliomas, or oligoastrocytomas, depending on the oncogenic stimuli [9] [10] [11] [12] [13] [14] [15] [16] . These studies highlight the potential genetic mutations which could be responsible for tumor initiation and development. On the other hand, recent studies have shown that signals from environment can also initiate and mediate tumor growth, as nestinpositive neonatal neural progenitors retrovirally over-expressing PDGF-B generate pure oligodendroglioma, whereas targeting GFAP-expressing glial progenitors gives rise to several types of tumors [17, 18] . In order to complement these genetically-induced tumor studies, we here investigated the 'cell of origin' of low-grade glioma in a far known rat model which spontaneously develops glioma in response to transplacental exposure to the DNA alkylating agent N-ethyl-N-nitrosourea (ENU) [19] [20] [21] [22] [23] . ENU-induced tumors have morphological and biological features similar to human glioma [22, 24] . ENU-induced tumors mimic the evolution and development of a brain tumor upon a sporadic exposure to carcinogens and neoplasms appear after several months of latency, thus helping with the understanding of early events occurring during gliomagenesis. In this study, we performed longitudinal MRI analysis of ENU-induced glioma over a period of 11 months combined with full characterization of tumor cells at different developmental stages. We identified a new slow dividing NG2 cell population, expressing early markers of oligodendroglial lineage and compromised in their differentiation, in low-grade glioma. In vitro, these cells exhibited multipotential abilities. In postnatal/adult brain NG2-expressing cells are strongly associated with fast dividing oligodendrocyte progenitor cells (OPC) [25] .
However, heterogeneity of NG2+ cell population has been demonstrated in several occasions. Bouslama-Oueghlani provided evidence that two types of NG2+ cells are present in developing brain, one highly proliferating and able to myelinate axons, and one almost quiescent with a reduced ability to produce myelin [26] . Recent studies have also demonstrated that early postnatal NG2 + cells are able to form passageable neurospheres
Materials and methods

Antibodies
The following primary antibodies were used : IQGAP1 (H109, rabbit, Secondary antibodies conjugated to cyanine 3 or cyanine 5 were from Jackson Laboratories (Interchim, France), secondary antibodies conjugated to Alexa Fluo 488 were from Molecular Probes (Invitrogen, France) and biotinylated anti-goat secondary antibody was from Southern Biotech.
Chemo-induced tumorigenesis
All procedures on animals were approved by the Rhône-Alpes Committee for Animal Experimentation Ethics (CREEA). OFA Sprague-Dawley pregnant rats were obtained from Charles River Laboratories (France). Pregnant rats were injected i.v. via the tail vein with 60mg/kg Ethylnitrosourea (Sigma-Aldrich) at gestational day E19. Five independent ENU injections were done over a period of 3 years, including two to four pregnant animals per experiment.
Magnetic Resonance Imaging (MRI) of rat brains
MRI images were obtained with a 2.35T magnet using a volume coil for transmission and a surface coil for reception. Anesthetized rats were placed in a cradle and their head was maintained with ear bars and a bite bar. For each animal, 20 contiguous 1 mm-thick slices, were acquired using a T2-weighted spin-echo sequence (TR/TE=2000/80ms, matrix=256*192 or 128*128, 2 accumulations, FOV=30x30 mm 2 ).
Tumor Growth Profile
Tumor volume was calculated using Image J software. Tumor surface (mm 2 ) was measured on MRI images according to MRI resolution. Tumor volume was calculated by analyzing the surface of the tumor on successive MRI slices multiplied by slice thickness (1 mm).
Two-way Anova statistical analysis was done using Sigma Stat software. Holm-Sidak tests were used for post-hoc multiple comparisons.
Immunohistochemistry/immunofluorescence
3-to-12-months old animals were deeply anesthetized with 5% isoflurane and killed by decapitation. Brains were immediately frozen in isopentane at -80°C. 10-μm cryosections were cut and postfixed in 4% paraformaldehyde. Sections were colored with hematoxylin and eosin for histological analysis. Alternatively, cryosections were permeabilized in TBS-0.2% Triton and blocked in TBS-5% goat serum. After overnight incubation with primary antibodies, sections were stained with secondary antibodies and counterstained with nuclear marker Hoechst 33258 (1μg/mL) when desired. Images were obtained with a Carl Zeiss Axiovert 200M microscope and with a Leica (TCS SP2) confocal microscope.
Cells or glioma explants were fixed using 4% paraformaldehyde and procedures were the same as brain slices except that incubation times for primary and secondary antibodies were reduced to 1 hour each. Antibodies for cell surface markers, such as A2B5 and O4, were added to culture medium for 1h before cell fixation.
Oligodendroglioma-derived cell culture
After MRI localization, tumors were excised from freshly dissected rat brains. They were cut in explants and plated onto poly-L-lysine treated glass coverslips, either in proliferation medium with 10ng/mL PDGF and 1 µg/mL bFGF, or in differentiation medium where PDGF and bFGF were replaced by 30ng/mL T3, 5ng/mL CNTF and 5μm Forskolin (as 
Rat brain tumor irradiation
Irradiation was performed at the Biomedical beamline of the European Synchrotron Radiation Facility (ESRF). Irradiation was performed with monochromatic synchrotron radiation, emitted from a wiggler multipole magnet. The energy used was 80 keV with a bandwidth of ΔE/E = 10 -3 . The dose delivered to tumors was 15 Gy. The irradiated volume covered a whole hemisphere and it was performed in tomotherapy mode, i.e. rotating the animal in the beam. The animals were anesthetized for irradiation and held vertically in a plastic frame, which kept their heads fixed. Beam dimensions were 1 mm vertical and 10 mm horizontal. Therefore, multistage irradiations were performed to cover the total volume of the brain hemisphere, typically 15 mm in length and 10 mm in diameter.
Results
Spatial and temporal emergence and development of rat chemically-induced brain tumors.
In this study, we used a well-established experimental model of brain tumors in which rats exposed in utero to a single dose of a mutagen, the N-Ethyl-N-NitrosoUrea (ENU) preferentially develop brain tumors [19, 22, 24] . This model has also the advantage of retracing basic events of carcinogenesis following a random exposure to mutagens or chemicals. The latency before appearance of brain tumor enables to address early events occurring in brain tumor genesis. Moreover, the drug is rapidly degraded in vivo thus avoiding any side effects causing by inflammatory response [31] . Six months to eleven months after exposure, some exposed animals exhibited severe neurological symptoms and the post-mortem examination revealed the presence of peripheral tumors and/or highly invasive brain tumors. These animals were no further investigated. We focused on exposed rats which showed no pathological evidence of tumor formation, hypothesizing that these 
Slowly proliferating rat glioma display features of oligodendroglioma.
We have previously shown that the most aggressive rat glioma (Type 3) have histologic and immunophenotypic characteristics that resemble human glioblastoma [5] . Both rat and human glioblastoma are characterized by niches of tumorigenic cells which express nestin and IQGAP1 [4, 5] . We here focused on further characterizing lower aggressive rat gliomas (Type 1 and Type 2) in order to identify the potential tumor initiating cells. (Figure 5e-f) . Such aberrant patterns of expression were independent of culture conditions. These observations emphasize the transformed character of these NG2-expressing tumoral precursor cells.
Overall, these findings suggest that ENU preferentially targets NG2+ multipotent precursor cells which results in an impairment and/or aberrant differentiation of their progeny rather than an increase in cell proliferation.
A few tumoral NG2+ cells are resistant to radiations.
Currently, therapies for human low-grade gliomas include observation, resection, radiation and chemotherapy. Radiotherapy extends survival but total remissions are rarely observed [40] . In order to determine the response of ENU-induced glioma to radiotherapy, five rats aged of 6 months and carrying low grade glioma were irradiated with a 15 Gy dose in whole brain hemispheres and followed up by MRI for up to 4 months after treatment. From MRI examination, three rats showed an apparent total tumor regression 137 days upon treatment (Figure 6a-b) . Nevertheless, the histological analysis of irradiated tissues revealed the presence of remnant tumor cells which resisted radiations (Figure 6c-d) .
Among those surviving cells, 87.6% and 82.6% express Sox10 and Olig2 markers respectively (Figure 6d ). On the other hand, the stem cell markers, nestin and IQGAP1
were still exclusively present in blood vessels. These results suggest that rat low grade glioma are in their majority radiosensitive, as observed for human oligodendroglioma, but some radio-resistant tumor cells persist and could be responsible for tumor recurrence.
Discussion
Here we used a rat model that develops glioma following in utero exposure to the mutagenesis agent N-ethyl-N-nitrosurea to investigate the potential origin of low-grade glioma. Although genetic mutations induced by ENU may be difficult to identify [24] , this model provides useful insights about the early events that precede glioma formation and may thus be helpful to identify cells of origin for glioma. Rat low grade gliomas represent the major asymptomatic neoplasic lesions (67%) 6 months after exposure to ENU.
Longitudinal imaging analysis revealed that after a latency period of 6 months, some low grade glioma developed into more aggressive tumors (referred as Type 2). Taking into account that both tumor subtypes developed with high frequency in the same brain regions (Supplemental Figure 1) , it is likely that they might have the same origin. Such modifications in tumor characteristics could be due to changes in tumor environment or to additional mutations. [7] . Rat glioma cells were able to express the neuronal marker βIII-tubulin (Figure 5f ) which would explain why oligodendroglioma frequently display immunohistochemical and ultrastructural features of neuronal cells [46] . Moreover, we demonstrated that rat glioma cells exhibit aberrant co-expression of both astrocytic and oligodendroglial cell lineage markers (Figure 5e ), thus providing a rationale for similar genetic signatures identified in both astrocytic and oligodendrocytic components in mixed human oligoastrocytoma [47] . Although one has to be cautious before extrapolating rat models to human pathologies, similarities between rat low grade glioma and human oligodendroglioma might provide clues to explain some characteristics of the human disease and further understand how glioma emerge and develop over time in order to design new therapies aiming at curing brain tumors. 
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